We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Roche Files IND for Genmab Antibody

Roche Files IND for Genmab Antibody

Roche Files IND for Genmab Antibody

Roche Files IND for Genmab Antibody

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Roche Files IND for Genmab Antibody"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Genmab A/S has announced that its partner Roche has filed an Investigational New Drug application (IND) with the US Food and Drug Administration for a Genmab antibody developed under the companies' collaboration.

This is the ninth milestone Genmab has achieved under the agreement. Genmab will receive a milestone payment from Roche which does not influence Genmab's financial guidance for 2005.

Under the agreement with Roche, Genmab utilizes its broad antibody expertise and development capabilities to create human antibodies to a broad range of disease targets identified by Roche.

Genmab receives milestone and royalty payments based on products. In certain circumstances, Genmab may obtain rights to develop products based on disease targets identified by Roche.

If all goals are reached, the value of the collaboration to Genmab could be USD 100 million, plus royalties.

Roche has selected four Genmab antibodies as clinical candidates and this is the first of the four to enter the clinic.

"This is the sixth Genmab product to enter clinical development," said Lisa N. Drakeman, Chief Executive Officer of Genmab.

"This move to clinical development is a testament to Genmab's antibody discovery skills as well as Roche's skill in identifying valid disease targets."